Advanced Search
KONG Tiandong, CHEN Lu, DUAN Fangfang, WANG Liuyan, ZHOU Hanli, ZHAO Xiaoli, LIU Mengmeng, LIU Danna. Relation Between CD8+T Lymphocyte Infiltration and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(5): 484-488. DOI: 10.3971/j.issn.1000-8578.2021.20.1191
Citation: KONG Tiandong, CHEN Lu, DUAN Fangfang, WANG Liuyan, ZHOU Hanli, ZHAO Xiaoli, LIU Mengmeng, LIU Danna. Relation Between CD8+T Lymphocyte Infiltration and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(5): 484-488. DOI: 10.3971/j.issn.1000-8578.2021.20.1191

Relation Between CD8+T Lymphocyte Infiltration and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

Funding: 

Science and Technology Foundation of Henan Province 172102310455

Science and Technology Foundation of Zhengzhou City 20130532

More Information
  • Corresponding author:

    LIU Danna, E-mail: 15427316@qq.com

  • Received Date: October 13, 2020
  • Revised Date: February 16, 2021
  • Available Online: January 12, 2024
  • Objective 

    To investigate the relation between the characteristics of CD8+T lymphocyte infiltration and the prognosis of triple-negative breast cancer patients.

    Methods 

    We retrospectively analyzed the clinicopathological data of 126 patients with triple-negative breast cancer undergoing preoperative neoadjuvant chemotherapy. Immunohistochemical staining was used to analyze the relation between CD8+T lymphocyte infiltration and clinicopathological characteristics. Kaplan-Meier method was used to draw the survival curve, and Cox risk ratio regression model was used to analyze the prognostic factors affecting disease-free survival time (DFS).

    Results 

    High-density CD8+Tils was associated with age < 60 years old, high pathological grade and high clinical stage (P < 0.05). The pCR rate of high-density CD8+Tils group was higher than that of the low-density group (66.7% vs. 19.8%, P=0.000). The median DFS of the high-density group was significantly longer than that of the low-density group (49 vs. 25 months, P < 0.05). Multivariate analysis showed that high pathological grade, tumor diameter > 2 cm, lymph node metastasis, vascular invasion and CD8+Tils low-density infiltration were factors for poor prognosis (P < 0.05), and CD8+Tils was an independent prognostic factor.

    Conclusion 

    CD8+Tils may be an independent prognostic indicator for triple-negative breast cancer. The patients with high-density infiltration have high postoperative pCR rate, long DFS and better long-term efficacy.

  • Competing interests: The authors declare that they have no competing interests.

  • [1]
    Thorat MA, Balasubramanian R. Breast cancer prevention in high-risk women[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 65: 18-31. doi: 10.1016/j.bpobgyn.2019.11.006
    [2]
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
    [3]
    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
    [4]
    Blows FM, Driver KE, Schmidt MK, et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10, 159 Cases from 12 Studies[J]. PLoS Med, 2010, 7(5): e1000279. doi: 10.1371/journal.pmed.1000279
    [5]
    Jitariu AA, Cîmpean AM, Ribatti D, et al. Triple negative breast cancer: the kiss of death[J]. Oncotarget, 2017, 8(28): 46652-46662.   doi: 10.18632/oncotarget.16938
    [6]
    Camorani S, Fedele M, Zannetti A, et al. TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities[J]. Pharmaceuticals (Basel), 2018, 11(4): 123. doi: 10.3390/ph11040123
    [7]
    Park JH, Ahn JH, Kim SB. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies[J]. ESMO Open, 2018, 3(Suppl 1): e000357.
    [8]
    Ikeda Y, Kiyotani K, Yew PY, et al. Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer[J]. Oncol Rep, 2017, 37(5): 2603-2610. doi: 10.3892/or.2017.5536
    [9]
    Al-Saleh K, Abd El-Aziz N, Ali A, et al. Predictive and prognostic significance of CD8(+) tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy[J]. Oncol Lett, 2017, 14(1): 337-344. doi: 10.3892/ol.2017.6144
    [10]
    Ahn SG, Kim SJ, Kim C, et al. Molecular Classification of Triple-Negative Breast Cancer[J]. J Breast Cancer, 2016, 19(3): 223-230. doi: 10.4048/jbc.2016.19.3.223
    [11]
    Le Du F, Eckhardt BL, Lim B, et al. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?[J]. Oncotarget, 2015, 6(15): 12890-12908. doi: 10.18632/oncotarget.3849
    [12]
    Liu YR, Jiang YZ, Xu XE, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer[J]. Breast Cancer Res, 2016, 18(1): 33. doi: 10.1186/s13058-016-0690-8
    [13]
    Gooden MJM, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis[J]. Br J Cancer, 2011, 105(1): 93-103. doi: 10.1038/bjc.2011.189
    [14]
    Webb JR, Milne K, Nelson BH. Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8+ tumor-infiltrating lymphocytes in ovarian cancer[J]. Oncoimmunology, 2014, 3: e27668. doi: 10.4161/onci.27668
    [15]
    Sarrabayrouse G, Corvaisier M, Ouisse LH, et al. Tumor-reactive CD4+ CD8αβ+ CD103+ αβT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers[J]. Int J Cancer, 2011, 128(12): 2923-2932. doi: 10.1002/ijc.25640
    [16]
    Liu S, Lachapelle J, Leung S, et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer[J]. Breast Cancer Res, 2012, 14(2): R48. doi: 10.1186/bcr3148
    [17]
    林晶, 陈誉, 陈刚, 等. CD8+T细胞浸润与STATs家族活化在胃癌组织中表达及临床意义[J]. 临床肿瘤学杂志, 2019, 24(6): 548-553. doi: 10.3969/j.issn.1009-0460.2019.06.013

    Lin J, Chen Y, Chen G, et al. Expression and clinical significance of CD8+T cell infiltration and STATs family activation in gastric cancer[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2019, 24(6): 548-553. doi: 10.3969/j.issn.1009-0460.2019.06.013
    [18]
    卢慧敏, 王琰, 陈陆俊, 等. CD103+CD8+T细胞在结直肠癌组织中的浸润分布及其临床意义[J]. 中国肿瘤生物治疗杂志, 2019, 26(1): 50-57. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW201901009.htm

    Lu HM, Wang Y, Chen LJ, et al. Distribution of CD103+ CD8+T cell infiltration in colorectal cancer tissues and its clinical significance[J]. Zhongguo Zhong Liu Sheng Wu Zhi Liao Za Zhi, 2019, 26(1): 50-57. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW201901009.htm
    [19]
    de Groot AF, Blok EJ, Charehbili A, et al. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2019, 175(3): 605-615. doi: 10.1007/s10549-019-05195-y
  • Related Articles

    [1]LU Mei, YANG Xiaojuan, ZOU Jieya, GUO Rong, WANG Xin, ZHANG Qian, DENG Xuepeng, TAO Jianfen, NIE Jianyun, YANG Zhuangqing. Efficacy Prediction Model for Neoadjuvant Chemotherapy on Breast Cancer Based on Differential Genes Expression[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1071-1077. DOI: 10.3971/j.issn.1000-8578.2021.21.0414
    [2]DENG Kangli, CUI Diansheng, JIA Quan'an, LIU Sanhe, HUANG Lei, WEI Shaozhong. Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer[J]. Cancer Research on Prevention and Treatment, 2019, 46(4): 363-366. DOI: 10.3971/j.issn.1000-8578.2019.18.1002
    [3]WU Jianzhong, CHEN Lin, LIU Xiaoan, GAO Quangen, HUANG Weixian. Tumor-infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(11): 1114-1118. DOI: 10.3971/j.issn.1000-8578.2015.11.012
    [4]LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
    [5]ZHAI Jianpo, WANG Jianwei, WANG Haidong, MAN Libo. Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(10): 1129-1133. DOI: 10.3971/j.issn.1000-8578.2014.10.016
    [6]ZHANG Yanshou, LIU Yunjiang. Correlation between BCRP Expression and Efficacy of Neoadjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2014, 41(05): 434-438. DOI: 10.3971/j.issn.1000-8578.2014.05.020
    [7]Xiong Ruihua, Ren Qing, Tian Xiurong, Tang Xinyun. Clinical Research of Neoadjuvant Chemotherapy in Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 719-721. DOI: 10.3971/j.issn.1000-8578.2012.06.027
    [8]YANG Hai-song, HUANG Jian-jun. Effects of Neoadjuvant Chemotherapy on P-gp,GST-π Expression in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(02): 147-149. DOI: 10.3971/j.issn.1000-8578.2009.02.018
    [9]WANG Kun, WU Yi-long, ZHENG Deng-yun, LIAO Ning, ZU Jian, LI Xue-rui, LIN Xue-ting. Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients by Using Molecular Markers[J]. Cancer Research on Prevention and Treatment, 2008, 35(02): 118-120. DOI: 10.3971/j.issn.1000-8578.2039
    [10]WU Xu-feng, TAO Ning. Neoadjuvant chemotherapy in stage Ib~IIb carcinoma of the cervix:long-term follow-up[J]. Cancer Research on Prevention and Treatment, 2003, 30(05): 428-429. DOI: 10.3971/j.issn.1000-8578.2118
  • Cited by

    Periodical cited type(3)

    1. 李静. 三阴性乳腺癌术后复发转移的风险预测可视化模型构建及效能验证. 肿瘤基础与临床. 2024(03): 265-270 .
    2. 黄佳旭,黄锴源,孙何兴,梁元科,林豪雨. 三阴性乳腺癌新辅助化疗疗效预测研究进展. 解放军医学杂志. 2023(06): 729-734 .
    3. 吴春秀,易珺,曾丽君,管志华,朱萍华. CD8~+T细胞数量及其功能检测在乳腺癌的早期诊断及预后的应用. 现代诊断与治疗. 2023(20): 3077-3079 .

    Other cited types(0)

Catalog

    Figures(3)  /  Tables(2)

    Article views (1996) PDF downloads (720) Cited by(3)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return